Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

BACKGROUND: Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R. This multicenter phase 1/2 study evaluated the maximum tolerated dose (MTD), safety, and clinical activity of pacritinib in patients with myelofibrosis (MF) and other advanced my...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W., Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H. Joachim
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5146859/
https://ncbi.nlm.nih.gov/pubmed/27931243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0367-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky